UBX Unity Biotechnology: Forward P/S Multiple
The absence of debt and robust patent protection for Unity Biotechnology (UBX) have acted as growth catalysts, as confirmed by the precise GURU.Markets chart, where the forward P/S history shows 184.40 as the latest metric reading. This has solidified the success of senolytics in treating joints and eyes, confirming the company's status as a recognized leader in the field of combating cellular senescence.
UBX (Unity Biotechnology, Inc): analytical breakdowns and indicator data
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- debt level and financial liquidity data:
Debt to Equity Unity Biotechnology|UBX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Unity Biotechnology|UBX - Company Debts|Debt to Book Capitalization Ratio Unity Biotechnology, Inc|UBX - Long-Term Debt|Company Short-Term Debts Unity Biotechnology|Quick Liquidity Indicator unitybiotechnology.com
- financial results and valuation multiples details:
UBX - Company Net Income|Future Profit Unity Biotechnology|UBX - P/E Multiple|Forward P/E Multiple Unity Bio|UBX - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Unity Biotechnology, Inc|UBX - Operating profit before amortization|Net earnings per share (EPS TTM) Unity Biotechnology|UBX - Earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months unitybiotechnology.com|UBX - Earnings per share growth this year|Earnings growth forecast for next year Unity Biotechnology
- company sales and revenue statistics:
Summary company analytics:UBX (Unity Biotechnology, Inc.)
To identify fundamental sector leaders, analysts utilize forward business value relative to expected sales, which allows them to capture shifts in institutional sentiment and avoid asset impairment. This calculation measures the issuer's long-term attractiveness, as the forward price-to-sales valuation chart reflects the gap between the potential of an aging population and the current lack of commercial demand due to the clinical development stage of Unity Biotechnology (UBX).
Competitor analysis
Forward P/S Multiple TEM (Tempus AI, Inc.)|Qiagen NV (QGEN) - Market Cap to Future Revenue Ratio|Ionis Pharma - Forward P/S Multiple|Repligen Inc. (RGEN) - Forward Price-to-Revenue Multiple|RNA: Forward P/S Multiple|crisprtx.com - Forward Price to Sales|Price-to-Projected Revenue Ratio GeneDx|Market Cap to Projected Revenue RARE (Ultragenyx Pharmaceutical Inc.)|Price-to-Projected Revenue Ratio Beam Therapeutics Corp (BEAM)|SRPT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Twist Bioscience TWST|10xgenomics.com - Price-to-Projected Revenue Ratio|NTLA - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Stoke Therapeutics Inc|BLFS: Forward P/S Multiple|Projected Price to Revenue Wave Pharma WVE|Forward Price-to-Revenue Multiple MAZE|Market Cap to Future Revenue Ratio sionnatx.com SION|Forward Price-to-Revenue Multiple PRME (Prime Medicine)|Forward P/S Multiple Taysha Gene Therapies Inc (TSHA)|Forward P/S Multiple QURE (uniQure Corp)|MeiraGTx Corp - Price-to-Projected Revenue Ratio|RGNX: Forward Price-to-Revenue Multiple|SLDB (solidbio.com) - Market Cap to Projected Revenue|OCGN: Forward P/S Multiple|Market Cap to Projected Revenue PACB|Price-to-Projected Revenue Ratio Benitec|Market Cap to Projected Revenue DSGN (Design Corp)|Forward P/S Multiple RCKT|Forward P/S Multiple 4dmoleculartherapeutics.com (FDMT)|Lexeo Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple Korro Bio Inc. KRRO|EDIT - Price-to-Projected Revenue Ratio|SLN (Silence Therapeutics Corp) - Market Cap to Projected Revenue|PRQR: Forward P/S Multiple|CDXS - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple SGMO|NAUT (Nautilus Biotechnology Inc) - Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple MGX (Metagenomi, Inc)|DTIL - Market Cap to Future Revenue Ratio|Generation Bio - Forward Price-to-Revenue Multiple|Forward Price to Sales BOLD|Exicure Corp - Forward P/S Multiple|IMNN: Price-to-Projected Revenue Ratio|PHIO: Forward P/S Multiple|MBIO - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio TransCode Therapeutics Inc.|Market Cap to Future Revenue Ratio Bionano BNGO|Forward Price-to-Revenue Multiple APDN (Applied DNA Sciences, Inc.)|Price to Expected Revenue Ratio BLUE|Forward P/S Multiple IPA (ImmunoPrecise Antibodies Ltd.)|Omega Therapeutics Corp (OMGA) - Market Cap to Future Revenue Ratio|Singular Genomics Systems - Forward P/S Multiple|regulusrx.com (RGLS) - Forward Price-to-Revenue Multiple|SYRS: Forward P/S Multiple|Telesis Bio Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio TRACON
